GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Use of Concomitant Glucose-Lowering Therapies and Associated Treatment Results Observed in Clinical Trials of Twice-Daily Exenatide

(2012) Richard Pencek et al.   Endocrine Practice

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial

(2012) Baptist Gallwitz et al.   LANCET

Death during Intensive Glycemic Therapy of Diabetes: Mechanisms and Implications

(2011) Philip E. Cryer   AMERICAN JOURNAL OF MEDICINE

Serious Cardiovascular Outcomes in Diabetes

(2011) Natalia Yakubovich et al.   CIRCULATION

GLP-1 receptor agonists and HBA1ctarget of

(2011) K. Esposito et al.   CURRENT MEDICAL RESEARCH AND OPINION

Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability

(2011) A. J. Garber   DIABETES CARE

Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study

(2011) D. Russell-Jones et al.   DIABETES CARE

Evidence Linking Hypoglycemic Events to an Increased Risk of Acute Cardiovascular Events in Patients With Type 2 Diabetes

(2011) S. S. Johnston et al.   DIABETES CARE

DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes

(2011) Thomas Blevins et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells

(2011) Colin A. Leech et al.   PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY

Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes

(2010) Caroline M. Apovian et al.   AMERICAN JOURNAL OF MEDICINE

A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin

(2010) J. Liutkus et al.   DIABETES OBESITY & METABOLISM

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

(2010) A. Garber et al.   DIABETES OBESITY & METABOLISM

Self-reported experience of hypoglycemia among adults with type 2 diabetes mellitus (Exhype)

(2010) Billie Pettersson et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

(2010) Michaela Diamant et al.   LANCET

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

(2010) Richard M Bergenstal et al.   LANCET

Exenatide is Non-inferior to Insulin in Reducing HbA1c: An Integrated Analysis of 1423 Patients with Type 2 Diabetes

(2010) Thomas Blevins et al.   POSTGRADUATE MEDICINE

Glucose-dependent potentiation of mouse islet insulin secretion by Epac activator 8-pCPT-2’-O-Me-cAMP-AM

(2010) Grant G. Kelley et al.   Islets

GLUT2 mutations, translocation, and receptor function in diet sugar managing

(2009) Armelle Leturque et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Suppression of Sulfonylurea- and Glucose-Induced Insulin Secretion In Vitro and In Vivo in Mice Lacking the Chloride Transport Protein ClC-3

(2009) Dai-Qing Li et al.   Cell Metabolism

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

Roles of cAMP signalling in insulin granule exocytosis

(2009) S. Seino et al.   DIABETES OBESITY & METABOLISM

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

(2009) D. Russell-Jones et al.   DIABETOLOGIA

Exenatide Exhibits Dose-Dependent Effects on Glycemic Control over 12 Weeks in Japanese Patients with Suboptimally Controlled Type 2 Diabetes

(2009) Takashi KADOWAKI et al.   ENDOCRINE JOURNAL

Enhanced Rap1 Activation and Insulin Secretagogue Properties of an Acetoxymethyl Ester of an Epac-selective Cyclic AMP Analog in Rat INS-1 Cells

(2009) Oleg G. Chepurny et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mechanisms of biphasic insulin-granule exocytosis - roles of the cytoskeleton, small GTPases and SNARE proteins

(2009) Z. Wang et al.   JOURNAL OF CELL SCIENCE

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Glucose-Induced Cyclic AMP Oscillations Regulate Pulsatile Insulin Secretion

(2008) Oleg Dyachok et al.   Cell Metabolism

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study

(2008) T MORETTO et al.   CLINICAL THERAPEUTICS

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

Glucose and GLP-1 Stimulate cAMP Production via Distinct Adenylyl Cyclases in INS-1E Insulinoma Cells

(2008) Lavoisier S. Ramos et al.   JOURNAL OF GENERAL PHYSIOLOGY

Role of the cAMP sensor Epac as a determinant of KATPchannel ATP sensitivity in human pancreatic β-cells and rat INS-1 cells

(2008) Guoxin Kang et al.   JOURNAL OF PHYSIOLOGY-LONDON

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET

The Role of Incretins in Glucose Homeostasis and Diabetes Treatment

(2008) W. Kim et al.   PHARMACOLOGICAL REVIEWS

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

(2008) Helle Linnebjerg et al.   REGULATORY PEPTIDES